Menstrual and women's health is the main area connected here, and any felt benefit should be read together with the human evidence base.
Human evidence exists, but it is mostly in patient or disease contexts, so the score is handled conservatively.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Standalone side-effect signals and combination cautions are listed separately.
The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.
Paper IDs and full lists are private. Only study types and summaries are shown.
The results of the first comparison, involving 6708 births with information on NTDs and other infant outcomes, show a protective effect of daily folic acid supplementation (alone or in combination with other vitamins and minerals) in preventing N TDs compared
It is indicated that nationally representative data are needed to guide the development of nutrition interventions and public health programs, such as dietary diversification, micronutrient fortification and supplementation.
Folic acid's putative role in influencing the acquisition of epigenetic marks in the germline, acquired during embryogenesis, is discussed, as well as the role of FA in the management of cancerous disease.
Folate status data for WRA globally are limited and must be carefully interpreted due to methodological issues, and future surveys would benefit from using the microbiologic assay to assess folate status, along with assay‐matched cutoffs to improve monitoring
The human gut appears to have a very efficient capacity to convert reduced dietary folates to 5-MTHF but limited ability to reduce folic acid, which would suggest that humans are reliant on the liver for folic Acid reduction even though it has a low and highly
GOFA-DOX/HACPN could be deemed as a safe and efficient intratumoral drug delivery system for breast cancer therapy because of its anti-tumor efficacy and the targeting effect of FA, which resulted in enhanced in vitro cytotoxicity.